Mirum maps FDA path after anti-itch candidate scores ph. 2 win
Mirum Pharmaceuticals is moving toward an FDA filing after its small molecule volixibat significantly reduced severe itching in patients with a rare liver disea...
Mirum Pharmaceuticals is moving toward an FDA filing after its small molecule volixibat significantly reduced severe itching in patients with a rare liver disease.